18632 Federal Register / Vol. 62, No. 73 / Wednesday, April 16, 1997 / Notices

College, Dr. Misra’s admission of certain

facts in that report, and ORI’s own

analysis, ORI found that Dr. Misra, a

former postdoctoral research associate,

Department of Chemistry, Dartmouth

College, engaged in scientific

misconduct by intentionally altering

laboratory notebook data entries for

research supported by a grant from the

National Institute of Environmental

Health Sciences (NIEHS), National

Institutes of Health (NIH).

Specifically, Dr. Misra altered

laboratory notebook data entries in two

instances in an effort to conceal prior

manipulations of that data without

disclosure or explanation to the

principal investigator or anyone else.

The experiment at issue involved an

assay of the chemical activity of a

carcinogen, and Dr. Misra’s change in

the readings of the ‘‘control’’

experiment, in which no carcinogen was

present, changed the results.

Dr. Misra has accepted the ORI

finding and has entered into a Voluntary

Exclusion Agreement with ORI in which

he has voluntarily agreed, for the three

(3) year period beginning April 7, 1997:

(1) To exclude himself from serving in

any advisory capacity to the Public

Health Service (PHS), including but not

limited to service on any PHS advisory

committee, board, and/or peer review

committee, or as a consultant; and

(2) That any institution that submits

an application for PHS support for a

research project on which Dr. Misra’s

participation is proposed or which uses

him in any capacity on PHS supported

research must concurrently submit a

plan for supervision of his duties. The

supervisory plan must be designed to

ensure the scientific integrity of Dr.

Misra’s research contribution. The

institution must submit a copy of the

supervisory plan to ORI.

No scientific publications were

required to be corrected as part of this

Agreement.

FOR FURTHER INFORMATION CONTACT:

Acting Director, Division of Research

Investigations, Office of Research

Integrity, 5515 Security Lane, Suite 700,

Rockville, MD 20852, (301) 443–5330.

Chris B. Pascal,

Acting Director, Office of Research Integrity.

[FR Doc. 97–9733 Filed 4–15–97; 8:45 am]

BILLING CODE 4160–17–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

National Vaccine Advisory Committee

(NVAC), Subcommittee on Vaccine

Safety, Subcommittee on Immunization

Coverage, Subcommittee on Future

Vaccines, and the Advisory

Commission on Childhood Vaccines

(ACCV) Subcommittee on Vaccine

Safety: Meetings

In accordance with section 10(a)(2) of

the Federal Advisory Committee Act

(Pub. L. 92–463), the Centers for Disease

Control and Prevention (CDC)

announces the following Federal

advisory committee meetings.

Name: National Vaccine Advisory

Committee (NVAC).

Times and dates: 8:45 a.m.–12:15 p.m.,

May 1, 1997. 8:30 a.m.–1:15 p.m., May 2,

1997.

Place: Hubert H. Humphrey Building,

Room 703A, 200 Independence Avenue, SW,

Washington, DC 20201.

Status: Open to the public, limited only by

the space available.

Notice: In the interest of security, the

Department has instituted stringent

procedures for entrance to the Hubert H.

Humphrey Building by non-government

employees. Thus, persons without a

government identification card should plan

to arrive at the building each day either

between 8 and 8:30 a.m. or 12:30 and 1 p.m.

so they can be escorted to the meeting.

Entrance to the meeting at other times during

the day cannot be assured.

Purpose: This committee advises and

makes recommendations to the Director of

the National Vaccine Program on matters

related to the Program responsibilities.

Matters to be discussed: Agenda items will

include a National Vaccine Program Office

(NVPO) update; a discussion on review of the

Department of Health and Human Services’

Adult Immunization Plan; a discussion on

the survey on practices of non-traditional

providers; a report of meeting on simianvirus-40—next steps; AIDS vaccine, the

progress in vaccine development and

organizational approach; the national vaccine

plan focusing on priorities; tuberculosis

vaccines, barriers and opportunites; the

National Institutes of Health (NIH) will

discuss their program on tuberculosis and

vaccine options; discussion from the

Advisory Council on the Elimination of

Tuberculosis; improving immunization

coverage report from the Sabin Foundation;

report from the Subcommittee on

Immunization Coverage; report from the

Subcommittee on Future Vaccines; report

from the Subcommittee on Vaccine Safety;

and status of the Work Group on

philosophical exemptions.

Agenda items are subject to change as

priorities dictate.

Name: Subcommittee on Vaccine Safety

and the Advisory Commission on Childhood

Vaccines, Subcommittee on Vaccine Safety.

Time and date: 1:15 p.m.–5 p.m., May 1,

1997.

Place: Hubert H. Humphrey Building,

Room 425A, 200 Independence Avenue, SW,

Washington, DC 20201.

Status: Open to the public, limited only by

the space available.

Purpose: This joint NVAC/ACCV

subcommittee will review issues relevant to

vaccine safety and adverse reactions to

vaccines.

Matters to be discussed: This

subcommittee will discuss the update on the

Public Health Service vaccine safety

activities; vaccine safety surveillance

overview; vaccine safety funding; and agenda

items for next meeting.

Name: Subcommittee on Immunization

Coverage.

Time and date: 1:15 p.m.–5 p.m., May 1,

1997.

Place: Hubert H. Humphrey Building,

Room 423A, 200 Independence Avenue, SW,

Washington, DC 20201.

Status: Open to the public, limited only by

the space available.

Purpose: This subcommittee will identify

and propose solutions that provide a

multifaceted and holistic approach to

reducing barriers that result in low

immunization coverage for children.

Matters to be discussed: This

subcommittee will discuss the review of

recommendations from the document

‘‘Strategies to Sustain Immunization

Coverage’; and a discussion and finalization

of the recommendations.

Name: Subcommittee on Future Vaccines.

Time and date: 1:15 p.m.–5 p.m., May 1,

1997.

Place: Hubert H. Humphrey Building,

Room 405A, 200 Independence Avenue, SW,

Washington, DC 20201.

Status: Open to the public, limited only by

the space available.

Purpose: The Subcommittee on Future

Vaccines will develop policy options and

guide national activities which will lead to

accelerated development, licensure, and best

use of new vaccines in the simplest possible

immunization schedules.

Matters to be discussed: This

subcommittee will discuss an update on

vaccine procurement strategies and case

studies in vaccine development.

Contact person for more information:

Felecia D. Pearson, Committee Management

Specialist, NVPO, CDC, 1600 Clifton Road,

NE, M/S D50, Atlanta, Georgia 30333,

telephone 404/639–7250.

Dated: April 11, 1997.

John C. Burckhardt,

Acting Director, Management Analysis and

Services Office, Centers for Disease Control

and Prevention (CDC).

[FR Doc. 97–9902 Filed 4–15–97; 8:45 am]

BILLING CODE 4163–18–P